NHS Integration DERM AI is already deployed across 25 NHS primary and secondary care organisations and has a history of more than 230,000 patient assessments with over 20,000 cancers identified, indicating strong NHS adoption and potential for expansion within public healthcare networks.

Policy Endorsement DERM is recommended by NICE and holds the only Class III CE marked AI medical device for skin cancer, underscoring regulatory credibility that can ease procurement cycles and reassure hospital buyers.

Cost Efficiency Clinics and hospitals using DERM have reduced face-to-face secondary care appointments by up to 95 percent, presenting a compelling value proposition for cost containment and capacity management investors and payers.

Growth Partnerships Recent collaborations with Healthdirect, Nordic region partners, Bupa, and Freedom Health demonstrate a scalable partner strategy and appetite for remote dermatology and triage services across payer networks and private healthcare providers.

Expansion Opportunities Recent product launches such as DERM Zero and integration into Healthdirect via AI-assisted triage in consumer channels indicate opportunities to cross-sell to digital health platforms, health insurers, and international markets seeking autonomous skin cancer pathways.